Dosing context · Research models only
GHK-Cu Dosing, in Research Context
Concentrations and routes as studied in cells, animals, and small topical trials — described as study parameters, never as a usage schedule for any person.
GHK-Cu research dosing context: what was administered, to what, by which route
Every figure on this page is a study parameter — a GHK-Cu research dosing context, not a recommendation. GHK-Cu is a research peptide for any non-topical use; what follows is what the published literature administered, to which model, by which route.
The in-vitro concentrations are the most precise. Human fibroblast collagen synthesis responded across 10⁻¹² to 10⁻⁹ M, with onset between 10⁻¹² and 10⁻¹¹ M and a peak near 10⁻⁹ M [1]. Topical cosmetic and clinical formulations sit far higher by mass, roughly 0.05% to 2% (w/w) in creams, serums, and gels, because topical delivery has to overcome the skin barrier and only a fraction of the copper crosses it [5]. The human hair-loss RCT used a 5-ALA+GHK complex at 50–100 mg/mL applied to the scalp [4].
Rodent systemic studies span a wide range by route and model: intraperitoneal dosing in mouse pulmonary and fibrosis models from sub-microgram to milligram-per-kilogram, intranasal dosing around 15 mg/kg in aging and cognition models, and oral gavage at 20 mg/kg in a colitis model [3]. These are listed to show the breadth of the preclinical record, not to imply any of them maps onto human use.
Routes studied
GHK-Cu has been delivered by an unusually wide set of routes in research, which is itself informative about why topical and systemic data should not be conflated. The reviewed routes include topical (cream, serum, liposome, nano-lipid carrier, ionic-liquid microemulsion, wound dressing/hydrogel, and nanofiber), intraperitoneal for rodent systemic studies, intranasal for rodent cognitive studies, oral gavage for rodent colitis, intravenous and subcutaneous for rodent pharmacokinetics, and intradermal or microneedle delivery in hair studies [3]. Topical is the route with the strongest human evidence and the clearest regulatory standing; the systemic routes are preclinical, and injectable human protocols circulating in community contexts have no peer-reviewed pharmacokinetic basis [3].
Half-life and clearance
No rigorous human pharmacokinetic half-life has been published for GHK-Cu [3]. The free tripeptide (340.38 Da) is rapidly cleared by plasma peptidases, and a rat study documented rapid metabolism of GHK to the dipeptide HK after intravenous dosing; secondary literature cites a short systemic elimination half-life on the order of 1–2 hours, with the copper-chelated complex more stable than the free peptide [3]. Topical application changes the picture by forming a dermal copper depot — about 97 µg/cm² retained over 48 hours in the human penetration study — which gives prolonged local availability even though the systemic peptide is short-lived [5]. The honest summary: short systemic persistence for free GHK, greater stability for the chelate, and a sustained local depot under the skin.
Stability and formulation
The GHK-Cu complex has a very high copper stability constant (log K ≈ 16.4), far higher than free GHK, which limits pro-oxidant free-copper release and keeps the complex intact [3]. It is most stable near pH 5–6.5 at a 1:1 copper-to-peptide ratio, and the blue-violet color of a reconstituted solution is the expected Cu(II) absorption signature of an intact complex; brown or green shifts indicate oxidation or precipitation [3]. Strong reducing agents such as ascorbic acid below about pH 3.5 reduce Cu(II) and break the complex, and AHAs, BHAs, and other low-pH actives can destabilize it or compete for copper [3]. Because free GHK is highly hydrophilic (clogP −2.24), passive stratum-corneum penetration is limited; palmitoylation (Pal-GHK, clogP ≈ 1.14), liposomal encapsulation, ionic-liquid microemulsions, and microneedle pretreatment are the delivery strategies the literature evaluates to improve it [3][15].
Human clinical data, in brief
Human evidence is predominantly topical and dermatologic: small placebo-controlled facial cream and serum trials (roughly n = 20–71) reporting improved skin density, firmness, fine lines, and wrinkle depth, plus the six-month n = 45 ALAVAX hair-loss trial showing significant hair-count gains versus placebo [4]. There are no completed Phase 2 or Phase 3 trials for systemic or injectable GHK-Cu; a topical wound-healing trial, CuHeal (NCT07437586), has been registered [16]. The absence of systemic human pharmacokinetic and efficacy data is the single largest gap in the record, and it is why this page frames everything as research context.